| Income Statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
| Research and development expenses | 697 | 420 | 462 | 568 |
| General and administrative expenses | 1,687 | 2,589 | 1,987 | 1,961 |
| Impairment of intangible assets | 13,533 | - | - | - |
| Loss from operating activities | -15,917 | -3,009 | -2,449 | -2,529 |
| Foreign exchange (loss) gain | -14 | -7 | 4 | -8 |
| Change in fair value of derivative warrant liabilities | 0 | 0 | 40 | -1,427 |
| Interest and other income, net | 141 | 138 | 170 | 172 |
| Total other income (expense), net | 127 | 131 | 134 | 1,591 |
| Loss before income tax benefit | -15,790 | -2,878 | -2,315 | -938 |
| Income tax benefit | 0 | -1,700 | 0 | 0 |
| Net loss | -15,790 | -1,178 | -2,315 | -938 |
| Basic EPS | -0.91 | -0.068 | -0.14 | -0.06 |
| Diluted EPS | -0.91 | -0.068 | -0.14 | -0.06 |
| Basic Average Shares | 17,269,986 | 17,259,864 | 16,933,620 | 15,924,522 |
| Diluted Average Shares | 17,269,986 | 17,259,864 | 16,933,620 | 15,924,522 |
Grace Therapeutics, Inc. (GRCE)
Grace Therapeutics, Inc. (GRCE)